{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:35:22Z","timestamp":1783809322039,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118708","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:24:25Z","timestamp":1771604665000},"page":"118708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of HDM2004, a potent, selective and orally bioavailable HPK1 inhibitor for tumor immunotherapy"],"prefix":"10.1016","volume":"308","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-9586","authenticated-orcid":false,"given":"Zhimin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"E","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118708_bib1","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1101\/gad.10.18.2251","article-title":"Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK\/SAPK kinase cascade","volume":"10","author":"Hu","year":"1996","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2026.118708_bib2","article-title":"Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118708_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118708_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.ai.2015.09.006","article-title":"MAP4K family kinases in immunity and inflammation","volume":"129","author":"Chuang","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ejmech.2026.118708_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12026-012-8319-1","article-title":"HPK1 as a novel target for cancer immunotherapy","volume":"54","author":"Sawasdikosol","year":"2012","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ejmech.2026.118708_bib6","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118708_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001402","article-title":"Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor","volume":"9","author":"You","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2026.118708_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2026.118708_bib9","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1021\/acs.jmedchem.2c00172","article-title":"Hematopoietic progenitor kinase 1 in tumor immunology: a medicinal chemistry perspective","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116206","article-title":"Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody","volume":"267","author":"Zeng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib11","doi-asserted-by":"crossref","first-page":"16201","DOI":"10.1021\/acs.jmedchem.3c01571","article-title":"Design, synthesis, and pharmacological evaluation of isoindoline analogues as new HPK1 inhibitors","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/sj.gene.6364334","article-title":"A distinct inflammatory gene expression profile in patients with psoriatic arthritis","volume":"7","author":"Stoeckman","year":"2006","journal-title":"Genes Immun."},{"key":"10.1016\/j.ejmech.2026.118708_bib13","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1002\/jps.22674","article-title":"Development of a new permeability assay using low-efflux MDCKII cells","volume":"100","author":"Di","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2026.118708_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176184","article-title":"Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models","volume":"961","author":"Setsu","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118708_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543776.2021.1924671","article-title":"Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020)","volume":"31","author":"Linney","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118708_bib16","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.2c02038","article-title":"Design and synthesis of functionally active 5-Amino-6-Aryl-Pyrrolopyrimidine inhibitors of hematopoietic progenitor kinase 1","volume":"66","author":"Gallego","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib17","doi-asserted-by":"crossref","first-page":"17429","DOI":"10.1021\/acs.jmedchem.4c01325","article-title":"Discovery of BAY-405: an azaindole-based MAP4K1 inhibitor for the enhancement of T-Cell immunity against cancer","volume":"67","author":"Mowat","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib18","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1021\/acsmedchemlett.4c00319","article-title":"Discovery of GNE-6893, a potent, selective, orally bioavailable small molecule inhibitor of HPK1","volume":"15","author":"Tellis","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118708_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/acsmedchemlett.0c00660","article-title":"Discovery of orally active isofuranones as potent, selective inhibitors of hematopoetic progenitor kinase 1","volume":"12","author":"Degnan","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118708_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/acsmedchemlett.2c00241","article-title":"Potent and selective biaryl amide inhibitors of hematopoietic progenitor Kinase 1 (HPK1)","volume":"14","author":"Sokolsky","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118708_bib21","doi-asserted-by":"crossref","first-page":"22002","DOI":"10.1021\/acs.jmedchem.4c01930","article-title":"Discovery of PF-07265028, A selective small molecule inhibitor of hematopoietic progenitor Kinase 1 (HPK1) for the treatment of cancer","volume":"67","author":"Gallego","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acs.oprd.2c00384","article-title":"A convergent synthesis of HPK1 inhibitor GNE-6893 via palladium-catalyzed functionalization of a tetrasubstituted isoquinoline","volume":"27","author":"Stumpf","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2026.118708_bib23","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1021\/acs.jmedchem.4c02631","article-title":"Discovery and optimization of pyrazine carboxamide AZ3246, a selective HPK1 inhibitor","volume":"68","author":"Shields","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib24","doi-asserted-by":"crossref","first-page":"21520","DOI":"10.1021\/acs.jmedchem.4c02421","article-title":"Discovery of Pyridine-2-Carboxamides derivatives as potent and selective HPK1 inhibitors for the treatment of cancer","volume":"67","author":"Peng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib25","doi-asserted-by":"crossref","first-page":"18682","DOI":"10.1021\/acs.jmedchem.4c01906","article-title":"Discovery of novel PROTAC-based HPK1 degraders with high potency and selectivity for cancer immunotherapy","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib26","doi-asserted-by":"crossref","first-page":"13852","DOI":"10.1021\/acs.jmedchem.4c00644","article-title":"Discovery of an exceptionally orally bioavailable and potent HPK1 PROTAC with enhancement of antitumor efficacy of Anti-PD-L1 therapy","volume":"67","author":"Wu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib27","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.4c02972","article-title":"Discovery of a new and selective HPK1 PROTAC for enhancing tumor immunotherapy through eliminating GLK degradation","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymeth.2023.12.009","article-title":"Application scenario-oriented molecule generation platform developed for drug discovery","volume":"222","author":"Zheng","year":"2024","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2026.118708_bib31","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1021\/acs.jcim.0c01329","article-title":"A cloud computing platform for scalable relative and absolute binding free energy predictions: new opportunities and challenges for drug discovery","volume":"61","author":"Lin","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118708_bib28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1095920","article-title":"Protein kinase inhibitors: insights into drug design from structure","volume":"303","author":"Noble","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118708_bib29","first-page":"5326","article-title":"Cyclin-dependent kinase (CDK) inhibitors: structure\u2013activity relationships and insights into the CDK2 selectivity of 6-substituted 2-arylaminopurines","volume":"55","author":"Martin","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118708_bib32","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.118708_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1107\/S2053230X20016015","article-title":"Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1)","volume":"77","author":"Lau","year":"2021","journal-title":"Acta Crystallogr. F Struct. Biol. Commun."},{"key":"10.1016\/j.ejmech.2026.118708_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118708_bib35","series-title":"Chemical Computing Group ULC, Molecular Operating Environment (MOE)","year":"2024"},{"key":"10.1016\/j.ejmech.2026.118708_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymeth.2023.12.009","article-title":"Application scenario-oriented molecule generation platform developed for drug discovery","volume":"222","author":"Zheng","year":"2024","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2026.118708_bib37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1021\/acs.jctc.3c00920","article-title":"Development and comprehensive benchmark of a high-quality AMBER-consistent small molecule force field with broad chemical space coverage for molecular modeling and free energy calculation","volume":"20","author":"Xue","year":"2024","journal-title":"J. Chem. Theor. Comput."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:13:35Z","timestamp":1779743615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"alternative-id":["S0223523426001534"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118708","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of HDM2004, a potent, selective and orally bioavailable HPK1 inhibitor for tumor immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118708"}}